First Wave Biopharma Announced Research Generated From Two Previously Completed Phase 2 Clinical Trials Of Latiglutenase Has Been Published In The Special Issue In The Peer-reviewed Scientific Journal
First Wave Biopharma Announced Research Generated From Two Previously Completed Phase 2 Clinical Trials Of Latiglutenase Has Been Published In The Special Issue In The Peer-reviewed Scientific Journal
First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients
BOCA RATON, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase
BOCA RATON, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
HC Wainwright & Co. Reinstates Neutral on First Wave BioPharma
HC Wainwright & Co. analyst Yi Chen reinstates First Wave BioPharma (NASDAQ:FWBI) with a Neutral.
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference
Poster presentations to highlight new quantitative and serologic diagnostic methods for Celiac Disease detection and determination of intestinal mucosal health New tools may serve as companion diagnostics for
First Wave BioPharma Is Maintained at Buy by Roth MKM
First Wave BioPharma Is Maintained at Buy by Roth MKM
Roth MKM Maintains Buy on First Wave BioPharma, Lowers Price Target to $36
Roth MKM analyst Jonathan Aschoff maintains First Wave BioPharma (NASDAQ:FWBI) with a Buy and lowers the price target from $40 to $36.
First Wave BioPharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/15/2024 627.27% Roth MKM $40 → $36 Maintains Buy 01/03/2024 708.08% Roth MKM $11 → $40 Maintains Buy 09
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersBetter Therapeutics (NASDAQ:BTTX) shares increased by 85.4% to $0.06 during Friday's pre-market session. The market value of their outstanding shares is at $3.5 million. Madrigal Pharmaceutical
Sector Update: Health Care Stocks Retreating Late Afternoon
Health care stocks fell late Thursday afternoon with the NYSE Health Care Index shedding 0.7% and the Health Care Select Sector SPDR Fund (XLV) down 0.4%. The iShares Biotechnology ETF (IBB) declined
Sector Update: Health Care
Health care stocks were slipping late Thursday afternoon, with the NYSE Health Care Index shedding 0.5% and the Health Care Select Sector SPDR Fund (XLV) down 0.9%. The iShares Biotechnology ETF (IBB)
First Wave BioPharma Shares Fall After Acquiring ImmunogenX
First Wave BioPharma (FWBI) shares were down nearly 20% in recent Thursday trading after the company said it has acquired ImmunogenX in an all-stock deal. The combined company will focus on advancing
WIMI, FWBI and BMR Among Mid-day Movers
First Wave BioPharma Acquires ImmunogenX to Bolster GI Pipeline
First Wave BioPharma Completes Merger Deal With ImmunogenX Adding Phase 3-Ready Candidate For Celiac Disease
First Wave BioPharma Inc (NASDAQ:FWBI) has acquired ImmunogenX in an all-stock transaction with the combined company focused on advancing a gastrointestinal (GI) pipeline.First Wave BioPharma signed a
First Wave BioPharma to Participate In 'Fireside Chat' at the 36th Annual Roth Conference
BOCA RATON, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
JAGX, BBAI and BNTC Among Mid-day Movers
First Wave BioPharma Shares Drop 25% After Direct Offering Prices
By Chris Wack First Wave BioPharma shares were down 25% to $6.98 in premarket trading after the company entered into a definitive securities purchase agreement with a certain institutional investor f
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersQuoin Pharmaceuticals (NASDAQ:QNRX) stock rose 71.1% to $4.74 during Monday's pre-market session. The market value of their outstanding shares is at $4.6 million. Ainos (NASDAQ:AIMD) shares mov
Press Release: First Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds in Registered Direct Offering
First Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds in Registered Direct Offering BOCA RATON, Fla., March 04, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ
No Data